Gynecologic Cancer
Conference Coverage
Preliminary data show similar declines in worry, low regret with RRSO and RRS/RRO
HONOLULU – Early findings from the TUBA trial suggest similar declines in worry among women with BRCA1/2 mutations who undergo risk-reducing...
Conference Coverage
Financial toxicity may be common in gynecologic cancer patients
HONOLULU – A small survey suggests financial toxicity may be common among gynecologic cancer patients starting a new line of treatment.
Conference Coverage
Tumor testing cost-effective for triage to germline testing in HGSOC patients
HONOLULU – Tumor testing for the triage of women with high-grade serous ovarian cancer to confirmatory genetic...
Conference Coverage
ENGOT-OV16/NOVA trial: Analysis shows improved TWiST with niraparib
An analysis of ENGOT-OV16/NOVA trial data showed improved time without toxicity and symptoms (TWiST) in patients with recurrent ovarian cancer...
Conference Coverage
Brachytherapy proves beneficial regardless of treatment duration
HONOLULU – The median overall survival was better among patients who received brachytherapy for 8 weeks or longer...
Conference Coverage
Financial assistance programs may speed treatment for cervical cancer
HONOLULU – Financial assistance programs may help lower-income cervical cancer patients complete treatment in a...
From the Journals
Ovarian cancer survivors carry burden of severe long-term fatigue
Women who have survived epithelial ovarian cancer (EOC) more often report severe long-term fatigue than healthy women, according to a case-control...
From the Journals
Researchers characterize novel subtype of endocervical adenocarcinoma
Gastric-type mucinous carcinoma is a distinct variant of endocervical mucinous adenocarcinoma significantly associated with poor clinical outcomes...
From the Journals
No survival benefit from systematic lymphadenectomy in ovarian cancer
Systematic pelvic and para-aortic lymphadenectomy does not appear to provide a survival benefit to women with advanced ovarian cancer and normal...
From the Journals
Mucinous ovarian tumor survival rates stress correct diagnosis
Women with invasive, well-differentiated mucinous ovarian cancer are more likely to die from their disease within 10 years of diagnosis than women...
Opinion
What is the ‘microbiome’ and how may it influence gynecologic cancers?
Investigators are seeking to establish the microbiome of normal uteri to accurately compare it with malignant uteri.